Skip to main content
Premium Trial:

Request an Annual Quote

EU Approves Celera's HCV Genotyping Test

NEW YORK (GenomeWeb News) – The Europen Union awarded the CE Mark to Celera Genomics' hepatitis C virus genotyping test, parent Applera said today.
 
Celera developed the RealTime HCV Genotype Assay with Abbott. It will be sold as part of this alliance. The test is designed to be used on Applied Biosystems' PRISM 7000 PCR system.
 
Called the Abbott RealTime HCV Genotype test, it complements the HCV quantitative viral load test available on Abbott’s m2000 system.
 
The regulatory approval allows the genotype assay to be sold in the European Union as a diagnostic product. This is the first real-time test for genotyping the HCV virus to obtain regulatory approval for commercial sale in Europe, Applera said.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.